← All indications
Thymus Neoplasms
Tumors or cancer of the THYMUS GLAND.
Subtype terms (1)
More specific conditions that are subtypes of Thymus Neoplasms in the MeSH hierarchy.
- Thymoma
78 drugs (50 approved, 28 experimental)
Drugs by status
Phase 3 trials (3)
Phase 2 trials (14)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (41)
- Celgene
- Merck
- Eli Lilly
- Genentech
- Novartis
- Crolll Gmbh
- Karyopharm Therapeutics Inc
- Tiziana Life Sciences, PLC
- Nerviano Medical Sciences
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- Huazhong University of Science and Technology
- Cornell University
- Eastern Cooperative Oncology Group
- European Thoracic Oncology Platform
- Georgetown University
- GSO Global Clinical Research BV
- Indiana University
- Johns Hopkins University
- Rutgers University
- Seoul National University
- Stanford University
- University of Lausanne
- University of Milan
- University of Regensburg
- Valley Health System
- University of Copenhagen
- University of Naples Frederico II
- University of Udine
- Istituto Clinico Humanitas - Rozzano (MI), Italy
- +11 more
Organization Involved with Phase 1 Indications (4)